Sign in

Colorectal cancer: trials that stopped early

Trials on Colorectal cancer that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.

Stopped early

254 stopped trials give a reason in the registry, latest registry update first. 4 more give no reason and are not listed.

  1. Terminated

    Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies

    Reason given in the registry

    “Business reasons”

    Quoted unchanged from ClinicalTrials.gov; record updated 30 Sept 2025.

    Ended
    Jan 2024
    Phase
    Phase 1
    Run by
    Novartis Pharmaceuticals
    Registry record
    NCT04000529
  2. Terminated

    Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT) in Recurrent Rectal Cancer

    Reason given in the registry

    “Slow enrollment”

    Quoted unchanged from ClinicalTrials.gov; record updated 29 Sept 2025.

    Ended
    Nov 2024
    Run by
    Washington University School of Medicine
    Registry record
    NCT04827732
  3. Terminated

    EO2040 in Combination With Nivolumab, for Treatment of Patients With Minimal Residual Disease of Colorectal Cancer

    Reason given in the registry

    “the study recruitment is significantly behind expectations as only one single patient has started treatment”

    Quoted unchanged from ClinicalTrials.gov; record updated 29 Sept 2025.

    Ended
    Jan 2024
    Phase
    Phase 2
    Run by
    Enterome
    Registry record
    NCT05350501
  4. Suspended

    Protocol to Validate the Performance of the LifeKit® Prevent Colorectal Neoplasia Test for CRC Screening

    Reason given in the registry

    “fundraising”

    Quoted unchanged from ClinicalTrials.gov; record updated 26 Sept 2025.

    Run by
    Metabiomics Corp
    Registry record
    NCT04693546
  5. Terminated

    Study of IK-595 in RAS- or RAF-altered Advanced Tumors

    Reason given in the registry

    “Limited resources and strategic priorities”

    Quoted unchanged from ClinicalTrials.gov; record updated 19 Sept 2025.

    Ended
    Sept 2025
    Phase
    Phase 1
    Run by
    Ikena Oncology
    Registry record
    NCT06270082
  6. Terminated

    A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors

    Reason given in the registry

    “The trial was terminated for strategic business reasons; the decision was not based on any safety and/or efficacy concerns.”

    Quoted unchanged from ClinicalTrials.gov; record updated 17 Sept 2025.

    Ended
    Feb 2025
    Phase
    Phase 1
    Run by
    Pfizer
    Registry record
    NCT06285097
  7. Terminated

    A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

    Reason given in the registry

    “Sponsor Decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 15 Sept 2025.

    Ended
    Feb 2025
    Phase
    Phase 1/2
    Run by
    Bolt Biotherapeutics, Inc.
    Registry record
    NCT04278144
  8. Terminated

    A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer

    Reason given in the registry

    “A pre-planned initial analysis concluded that the study was unlikely to achieve its primary objective of demonstrating superior progression-free survival. Based on the Steering Committee's recommendation, the Sponsor has closed the study.”

    Quoted unchanged from ClinicalTrials.gov; record updated 12 Sept 2025.

    Ended
    Aug 2024
    Phase
    Phase 2
    Run by
    NuCana plc
    Registry record
    NCT05678257
  9. Withdrawn

    A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies

    Reason given in the registry

    “PI left NIH.”

    Quoted unchanged from ClinicalTrials.gov; record updated 11 Sept 2025.

    Ended
    Sept 2025
    Phase
    Phase 2
    Run by
    National Cancer Institute (NCI)
    Registry record
    NCT06690281
  10. Withdrawn

    A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer

    Reason given in the registry

    “PI left NIH.”

    Quoted unchanged from ClinicalTrials.gov; record updated 11 Sept 2025.

    Ended
    Sept 2025
    Phase
    Phase 2
    Run by
    National Cancer Institute (NCI)
    Registry record
    NCT06410534
  11. Terminated

    Study of INCA 0186 in Subjects With Advanced Solid Tumors

    Reason given in the registry

    “This was a strategic business decision. There were no safety concerns contributing to this decision.”

    Quoted unchanged from ClinicalTrials.gov; record updated 2 Sept 2025.

    Ended
    Sept 2024
    Phase
    Phase 1
    Run by
    Incyte Corporation
    Registry record
    NCT04989387
  12. Withdrawn

    Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures

    Reason given in the registry

    “Discontinuation of molecule development”

    Quoted unchanged from ClinicalTrials.gov; record updated 2 Sept 2025.

    Ended
    Jul 2024
    Phase
    Phase 2
    Run by
    Institut Bergonié
    Registry record
    NCT06084689
  13. Terminated

    Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial

    Reason given in the registry

    “Low accrual”

    Quoted unchanged from ClinicalTrials.gov; record updated 29 Aug 2025.

    Ended
    Dec 2023
    Run by
    Academic and Community Cancer Research United
    Registry record
    NCT03765736
  14. Withdrawn

    Effect of ICCAUT Strategy on Postoperative Urinary Retention After Radical Rectal Cancer Surgery (ICCAUT-2)

    Reason given in the registry

    “The ICCAUT-1 trial failed to demonstrate the superiority of the ICCAUT strategy in urinary dysfunction. Therefore, there is no need to conduct subsequent trials.”

    Quoted unchanged from ClinicalTrials.gov; record updated 28 Aug 2025.

    Run by
    The First Hospital of Jilin University
    Registry record
    NCT06217016
  15. Terminated

    A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours

    Reason given in the registry

    “Sponsor reprioritization of active trials.”

    Quoted unchanged from ClinicalTrials.gov; record updated 24 Aug 2025.

    Ended
    Feb 2025
    Phase
    Phase 1
    Run by
    3B Pharmaceuticals GmbH
    Registry record
    NCT05605522
  16. Terminated

    Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors

    Reason given in the registry

    “Sponsor decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 14 Aug 2025.

    Ended
    Dec 2024
    Phase
    Phase 1
    Run by
    Day One Biopharmaceuticals, Inc.
    Registry record
    NCT07121829
  17. Terminated

    ZN-c3 in Adult Participants With Metastatic Colorectal Cancer

    Reason given in the registry

    “Study terminated due to change in therapeutic landscape.”

    Quoted unchanged from ClinicalTrials.gov; record updated 8 Aug 2025.

    Ended
    Jul 2025
    Phase
    Phase 1
    Run by
    K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
    Registry record
    NCT05743036
  18. Suspended

    Endorectal Brachytherapy for Rectal Cancer

    Reason given in the registry

    “Unknown time frame for availability of new endorectal probes”

    Quoted unchanged from ClinicalTrials.gov; record updated 1 Aug 2025.

    Phase
    Phase 2
    Run by
    University Hospital, Bordeaux
    Registry record
    NCT05591534
  19. Terminated

    A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer

    Reason given in the registry

    “Due to lack of efficacy shown at the time of the interim analysis.”

    Quoted unchanged from ClinicalTrials.gov; record updated 24 Jul 2025.

    Ended
    Jun 2024
    Phase
    Phase 2
    Run by
    SOTIO Biotech AG
    Registry record
    NCT05619172
  20. Terminated

    A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC

    Reason given in the registry

    “Drugs Unavailable”

    Quoted unchanged from ClinicalTrials.gov; record updated 22 Jul 2025.

    Ended
    Mar 2024
    Phase
    Phase 2
    Run by
    Patrick Boland
    Registry record
    NCT03547999
  21. Terminated

    A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors

    Reason given in the registry

    “At the time of study termination, both fruquintinib and tislelizumab are commercially available in the United States.”

    Quoted unchanged from ClinicalTrials.gov; record updated 14 Jul 2025.

    Ended
    Jun 2024
    Phase
    Phase 1/2
    Run by
    Hutchmed
    Registry record
    NCT04577963
  22. Terminated

    89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

    Reason given in the registry

    “Indication scouting for TLX250-CDx will continue in theranostic studies, with a therapeutic component in the study design.”

    Quoted unchanged from ClinicalTrials.gov; record updated 10 Jul 2025.

    Ended
    May 2025
    Phase
    Phase 2
    Run by
    Telix Pharmaceuticals (Innovations) Pty Ltd
    Registry record
    NCT05563272
  23. Terminated

    SafeHeal Colovac Colorectal Anastomosis Protection Device Evaluation (SAFE-2) Pivotal Study

    Reason given in the registry

    “Voluntary and temporary suspension of enrollment.”

    Quoted unchanged from ClinicalTrials.gov; record updated 3 Jul 2025.

    Ended
    Jan 2024
    Run by
    SafeHeal Inc
    Registry record
    NCT05010850
  24. Terminated

    A Phase II Randomized Therapeutic Optimization Trial for Subjects With Refractory Metastatic Colorectal Cancer Using ctDNA: Rapid 1 Trial

    Reason given in the registry

    “slow accrual”

    Quoted unchanged from ClinicalTrials.gov; record updated 1 Jul 2025.

    Ended
    Mar 2024
    Phase
    Phase 2
    Run by
    University of Florida
    Registry record
    NCT04786600
  25. Terminated

    A Study to Investigate LYL845 in Adults With Solid Tumors

    Reason given in the registry

    “Pipeline Reprioritization”

    Quoted unchanged from ClinicalTrials.gov; record updated 1 Jul 2025.

    Ended
    Jan 2025
    Phase
    Phase 1
    Run by
    Lyell Immunopharma, Inc.
    Registry record
    NCT05573035
  26. Suspended

    A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7

    Reason given in the registry

    “Business decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 27 Jun 2025.

    Ended
    Sept 2025
    Phase
    Phase 1
    Run by
    NextPoint Therapeutics, Inc.
    Registry record
    NCT05958199
  27. Withdrawn

    TCR1020-CD8 T Cells in KRAS-mutated Cancers

    Reason given in the registry

    “Administrative decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 25 Jun 2025.

    Phase
    Phase 1
    Run by
    University of Pennsylvania
    Registry record
    NCT06707896
  28. Terminated

    FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)

    Reason given in the registry

    “Business decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 25 Jun 2025.

    Ended
    Oct 2024
    Phase
    Phase 1
    Run by
    POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
    Registry record
    NCT05432193
  29. Terminated

    Evaluation of Ability to Detect Bowel Gas During Laparoscopic Right Colectomy With Intracorporeal Anastomosis

    Reason given in the registry

    “Need for device upgrade.”

    Quoted unchanged from ClinicalTrials.gov; record updated 6 Jun 2025.

    Ended
    Sept 2024
    Run by
    Weill Medical College of Cornell University
    Registry record
    NCT04964297
  30. Withdrawn

    A Pilot Study to Explore the Role of Gut Flora in Colorectal Cancer

    Reason given in the registry

    “Company shifted focus”

    Quoted unchanged from ClinicalTrials.gov; record updated 5 Jun 2025.

    Run by
    ProgenaBiome
    Registry record
    NCT04148378

Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.